Nuvation Bio Inc. (NUVB)

Market Cap	714.55M
Revenue (ttm)	10.96M
Net Income (ttm)	-606.38M
Shares Out	340.26M
EPS (ttm)	-2.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,964,623
Open	2.150
Previous Close	2.040
Day's Range	1.980 - 2.290
52-Week Range	1.540 - 3.970
Beta	1.42
Analysts	Strong Buy
Price Target	8.20 (+290.48%)
Earnings Date	May 7, 2025

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and ext...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 220
• Stock Exchange: NYSE
• Ticker Symbol: NUVB
• Website: https://www.nuvationbio.com

Analyst Forecast

According to 5 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price forecast is $8.2, which is an increase of 290.48% from the latest price.

Price Target

$8.2

(290.48% upside)

Analyst Consensus: Strong Buy